Similar articles

• The role of newer monoclonal antibodies in renal transplantation.

  Vincenti F. Vincenti F. Transplant Proc. 2001 Feb-Mar;33(1-2):1000-1. doi: 10.1016/s0041-1345(00)02303-4. Transplant Proc. 2001. PMID: 11267163 Review. No abstract available.
• Immunosuppressive [correction of immunosupressive] agents and their actions.

  First MR. First MR. Transplant Proc. 2002 Aug;34(5):1369-71. doi: 10.1016/s0041-1345(02)02893-2. Transplant Proc. 2002. PMID: 12176401 No abstract available.
• Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation.

  Ivanovski N, Popov Z, Kolevski P, Cakalaroski K, Spasovski G, Sikole A, Paneva-Masin J. Ivanovski N, et al. Transplant Proc. 2001 Nov-Dec;33(7-8):3203-4. doi: 10.1016/s0041-1345(01)02363-6. Transplant Proc. 2001. PMID: 11750374 No abstract available.
• Anti-interleukin 2-receptor antibodies: a comparative study with polyclonal antibodies in kidney transplantation: preliminary results.

  Martins L, Henriques AC, Dias L, Sarmento AM, Pereira MC, Guimarães S. Martins L, et al. Transplant Proc. 2000 Dec;32(8):2623-5. doi: 10.1016/s0041-1345(00)01810-8. Transplant Proc. 2000. PMID: 11134730 Clinical Trial. No abstract available.
• Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.

  Swiatecka-Urban A. Swiatecka-Urban A. Paediatr Drugs. 2003;5(10):699-716. doi: 10.2165/00148581-200305100-00005. Paediatr Drugs. 2003. PMID: 14510627 Review.